

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Boan Biotech**  
**博安生物**

## **Shandong Boan Biotechnology Co., Ltd.**

**山东博安生物技术股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 6955)**

### **(1) RESIGNATION OF EXECUTIVE DIRECTOR; AND (2) CHANGE IN COMPOSITION OF BOARD COMMITTEE**

#### **RESIGNATION OF EXECUTIVE DIRECTOR**

The board of directors (the “**Board**”) of Shandong Boan Biotechnology Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that, as Dr. Dou Changlin (“**Dr. Dou**”) has reached the statutory retirement age, he has voluntarily resigned from his positions as executive Director, President of Research and Development and Chief Operating Officer of the Company, and chairman of the Strategy Committee. Dr. Dou will not hold any other positions in the Company, its subsidiaries or its associated companies upon his resignation (the “**Resignation**”). The Resignation takes effect from 31 March 2026.

Dr. Dou has confirmed that he has no disagreement with the Board and that there are no other matters in respect of his Resignation that need to be brought to the attention of The Stock Exchange of Hong Kong Limited or the shareholders of the Company.

During his tenure of office, Dr. Dou carried out his responsibilities with diligence and dedication, and made positive contributions to the Company’s growth and development. The Board would like to express its sincere gratitude to Dr. Dou for his hard work and dedication during his term of office.

## **CHANGE IN COMPOSITION OF BOARD COMMITTEE**

The Board further announces that, with effect from 31 March 2026, Ms. Jiang Hua, Chairlady of the Board and an executive Director, has been designated as the chairlady of the Strategy Committee and Mr. Wang Shenghan, an executive Director, has been appointed as a member of the Strategy Committee such that the Strategy Committee will comprise of the following three members: Ms. Jiang Hua (as chairlady), Mr. Wang Shenghan and Mr. Shi Luwen.

By Order of the Board  
**Shandong Boan Biotechnology Co., Ltd.**  
**Jiang Hua**

*Chairlady, Chief Executive Officer and Executive Director*

Yantai, the People's Republic of China, 31 March 2026

*As at the date of this announcement, the executive directors of the Company are Ms. Jiang Hua and Mr. Wang Shenghan; the non-executive directors of the Company are Mr. Liu Yuanchong, Ms. Li Li and Mr. Li Shixu; and the independent non-executive directors of the Company are Professor Shi Luwen, Mr. Dai Jixiong and Dr. Yu Jialin.*